{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00028388", "CSN": null, "TRF": "ORD_1602304_01", "MRN": "49289125", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1301263", "clinicalId": "1302613", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1602304_01", "SampleName": "US1530025.01", "Version": "0", "Sample": {"FM_Id": "ORD_1602304_01", "SampleId": "US1530025.01", "BlockId": "S112-10816A", "TRFNumber": "ORD_1602304_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_04_03", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "60", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10083", "MRN": "49289125", "FullName": "\u59dc\u4fca\u744b", "FirstName": "Chun Wei", "LastName": "Chiang", "SubmittedDiagnosis": "Brain glioblastoma (GBM)", "Gender": "Male", "DOB": "1976_03_01", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u6797\u58eb\u5091", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2023_03_14", "ReceivedDate": "2023-04-14 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "EGFR"}, {"Gene": "IDH1"}]}, "Summaries": {"alterationCount": "9", "clinicalTrialCount": "17", "resistiveCount": "0", "sensitizingCount": "2"}, "VariantProperties": {"VariantProperty": [{"geneName": "NOTCH3", "isVUS": "true", "variantName": "M1663V"}, {"geneName": "SDHC", "isVUS": "true", "variantName": "M164L"}, {"geneName": "TSC2", "isVUS": "true", "variantName": "T1070M"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "PDGFRA", "Include": "true", "Alterations": {"Alteration": {"Name": "D842Y", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "16.96", "isEquivocal": "false", "name": "D842Y"}}, "Interpretation": "PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). PDGFRA exon 18 mutations at position D842 have been shown to be activating (Corless et al., 2005; 15928335, Dai et al., 2013; 24132921, Heinrich et al., 2012; 22745105, Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2008; 18955451, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, von Bubnoff et al., 2011; 20972453). Although PDGFRA D842V is associated with resistance to imatinib and sunitinib (Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666), several other mutations at this position, including D842E, D842H, and D842Y, were shown to be sensitive to imatinib in preclinical studies (von Bubnoff et al., 2011; 20972453, Corless et al., 2005; 15928335, Byrgazov et al., 2016; 27573554, Dai et al., 2013; 24132921, Heinrich et al., 2012; 22745105). PDGFRA mutation has been identified in 5.6% of Grade 3 and Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2023)(Tate et al., 2019; 30371878). PDGFRA mutations have been reported in 0_5% of lower grade glioma and glioblastoma samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890, cBio_Hoadley et al., 2018; 29625048, cBio_Ellrott et al., 2018; 29596782, cBio_Taylor et al., 2018; 29622463, cBio_Gao et al., 2018; 29617662, cBio_Liu et al., 2018; 29625055, cBio_Sanchez_Vega et al., 2018; 29625050, Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Thomas et al., 2017; 28472509, cBio_Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). PDGFRA amplification has been associated with tumor grade and poor PFS and OS for patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutations in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Koc\u00e1kov\u00e1 et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515).", "Include": "true", "ClinicalTrialNote": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Sorafenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P)(Roubaud et al., 2012; 22294526). </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Imatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence, PDGFRA activating mutations (Cassier et al., 2012; 22718859, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Heinrich et al., 2003; 14645423, Yoo et al., 2016; 26130666), fusions (Baccarani et al., 2007; 17666373, Curtis et al., 2007; 17555450, Griffin et al., 2003; 12808148, Helbig et al., 2009; 19120352, Klion et al., 2004; 14504092, Qu et al., 2016; 27120808, Metzgeroth et al., 2007; 17377585, Metzgeroth et al., 2008; 18950453, Ogbogu et al., 2009; 19910029, Sugimoto et al., 2015; 26319757), and expression (Frenard et al., 2016; 27051816) may predict sensitivity to imatinib. Although extensive clinical data in GIST associate PDGFRA D842V with resistance to imatinib (Cassier et al., 2012; 22718859, Debiec_Rychter et al., 2005; 15685537, Heinrich et al., 2003; 14645423, Heinrich et al., 2008; 18955451, Heinrich et al., 2008; 18955458, Heinrich et al., 2012; 22665524, Heinrich et al., 2012; 22745105, Yoo et al., 2015; 26130666), other missense mutations at this position are predicted to be sensitive to imatinib on the basis of preclinical data (von Bubnoff et al., 2011; 20972453, Corless et al., 2005; 15928335, Byrgazov et al., 2016; 27573554, Dai et al., 2013; 24132921, Heinrich et al., 2012; 22745105). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03970447", "Include": "true"}, {"nctId": "NCT04771520", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT04817956", "Include": "true"}, {"nctId": "NCT02379416", "Include": "true"}, {"nctId": "NCT01738139", "Include": "true"}, {"nctId": "NCT05036226", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "C136Y", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "20.08", "isEquivocal": "false", "name": "C136Y"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma (Zhou et al., 1999; 10096247, Rasheed et al., 1997; 9331072, Davies et al., 1999; 10188904, Smith et al., 2001; 11504770, Lin et al., 1998; 9796977, Schmidt et al., 1999; 10560660, Kato et al., 2000; 11051241, Furnari et al., 2007; 17974913). One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases (cBio_Brennan et al., 2013; 24120142), while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases (Cancer Genome Atlas Research Network., 2015; 26061751). Decreased PTEN expression is associated with the higher grade GBM tumors (Sano et al., 1999; 10213484). Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas (Lin et al., 1998; 9796977, Srividya et al., 2011; 21134002). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus (Galanis et al., 2005; 15998902, Kreisl et al., 2009; 19018475, Mason et al., 2011; 22160854). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04740190", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT05076513", "Include": "true"}, {"nctId": "NCT04614909", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT04991480", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CBL", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 1228_92_1231>G", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "32.38", "isEquivocal": "false", "name": "splice site 1228_92_1231>G"}}, "Interpretation": "CBL encodes an E3 ubiquitin protein ligase that is involved in cell signaling and ubiquitination, targeting proteins such as EGFR, FGFR1, FGFR2, PDGFR_alpha, PDGFR_beta, FLT3, and SRC for degradation by the proteasome (Bacher et al., 2010; 20195608, Miyake et al., 1999; 10347229, Polzer et al., 2012; 23127761, Levkowitz et al., 1998; 9851973, Bunda et al., 2013; 23400592). CBL alterations that result in loss or disruption of the tyrosine kinase binding domain, RING finger domain, and/or tail domain, as observed here, are predicted to be inactivating and to promote tumorigenesis (Andonoiou et al., 1994; 7925293, Aranaz et al., 2012; 22315494, Fernandes et al., 2010; 20622007, Grand et al., 2009; 19387008, Javadi et al., 2013; 23696637, Kassenbrock et al., 2004; 15117950, Levkowitz et al., 1999; 10635327, Loh et al., 2009; 19571318, Martinelli et al., 2010; 20619386, Saito et al., 2012; 22591685, Sanada et al., 2009; 19620960, Score et al., 2012; 22053108, Shiba et al., 2011; 21494262, Standaert et al., 2004; 15581361, Tan et al., 2010; 20126411, Thien et al., 2001; 11239464, Visser and Lill, 2005; 16246327, Li et al., 2016; 26676746). CBL mutation has been reported in <1% of lower grade glioma and glioblastoma samples (Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Brennan et al., 2013; 24120142). High expression of c_Cbl has been reported to correlate with poor prognosis in glioma (Jing et al., 2016; 27073553). In preclinical studies, CBL has been shown to promote glioma cell invasion and glioblastoma tumor growth in mice (Seong et al., 2014; 25450678, Stevens et al., 2014; 24458840). CBL inactivation may lead to the hyperactivation of various receptor tyrosine kinases (RTKs), including MET (Mancini et al., 2002; 11847211), PDGFRA (Miyake et al., 1998; 9653117), KIT (Masson et al., 2006; 16780420), VEGFR2 (Singh et al., 2007; 17372230), and the TAM (TYRO3, AXL, MER) RTKs (Paolino et al., 2014; 24553136). These RTKs are targets of the multikinase inhibitor sitravatinib (Patwardhan et al., 2016; 26675259), which has shown activity in CBL_mutated advanced solid tumors (Bazhenova et al., 2018; ESMO Abstract 408O). Among 8 patients with CBL inactivating alterations in a Phase 1b trial, sitravatinib produced 2 PRs (25% ORR), with 1 NSCLC and 1 melanoma responding for over 4 months, and 4 SD outcomes, with 3 prolonged SDs seen in a patient with NSCLC, a patient with esophageal cancer, and a patient with a pancreatic neuroendocrine tumor (Bazhenova et al., 2018; ESMO Abstract 408O). CBL has been shown to downregulate EGFR (Shtiegman et al., 2007; 17486068, Padr\u00f3n et al., 2007; 17699773, Hosaka et al., 2007; 17695511, Han et al., 2006; 16969069, Yang et al., 2006; 16849543) and FLT3 (Sargin et al., 2007; 17446348, Oshikawa et al., 2011; 21768087, Reindl et al., 2009; 19276253). Preclinical models of myeloid malignancies have demonstrated that CBL inactivation confers sensitivity to the FLT3_targeting therapies sunitinib (Sargin et al., 2007; 17446348), midostaurin (Reindl et al., 2009; 19276253), and quizartinib (Taylor et al., 2012; 22990016), as well as to dasatinib (Makishima et al., 2012; 22246246), although clinical evidence for this approach in solid tumors is lacking.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": {"Name": "p16INK4a R80* and p14ARF P94L", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "65.81", "isEquivocal": "false", "name": "p16INK4a R80* and p14ARF P94L"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here have been observed in the context of cancer but have not been characterized and their effect on p14ARF function is unclear. Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in glioblastoma (GBM) and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared with patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter OS in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "PDGFRA", "Alteration": "D842Y", "Title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "StudyPhase": "PHASE 2/3", "Target": "BRAF, VEGFRs, RET, KIT", "Locations": "Utah, California, Michigan, Pennsylvania, Massachusetts, Connecticut, New York, North Carolina, Alabama, Georgia", "NCTID": "NCT03970447", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Y", "Title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation_Positive Locally Advanced or Metastatic Malignant Solid Tumors", "StudyPhase": "PHASE 2", "Target": "KIT, PDGFRA", "Locations": "Texas", "NCTID": "NCT04771520", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Y", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Y", "Title": "Improving Public Cancer Care by Implementing Precision Medicine in Norway", "StudyPhase": "PHASE 2", "Target": "PD_L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K_alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL", "Locations": "Troms\u00f8 (Norway), Bod\u00f8 (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), F\u00f8rde (Norway), Bergen (Norway)", "NCTID": "NCT04817956", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Y", "Title": "Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors", "StudyPhase": "PHASE 1", "Target": "ABL, KIT", "Locations": "Maryland", "NCTID": "NCT02379416", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Y", "Title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "KIT, ABL, CTLA_4", "Locations": "Texas", "NCTID": "NCT01738139", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Include": "true"}, {"Gene": "PDGFRA", "Alteration": "D842Y", "Title": "COAST Therapy in Advanced Solid Tumors and Prostate Cancer", "StudyPhase": "PHASE 1/2", "Target": "DDR2, ABL, SRC, KIT, mTOR", "Locations": "South Carolina", "NCTID": "NCT05036226", "Note": "PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Talazoparib _ Carboplatin for Recurrent High_grade Glioma With DDRd", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Hong Kong (Hong Kong)", "NCTID": "NCT04740190", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Trial of Niraparib in Participants With Newly_diagnosed Glioblastoma and Recurrent Glioma", "StudyPhase": "PHASE null", "Target": "PARP", "Locations": "Arizona", "NCTID": "NCT05076513", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM", "StudyPhase": "PHASE null", "Target": "PARP", "Locations": "Arizona", "NCTID": "NCT04614909", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C136Y", "Title": "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PARP, Pol theta", "Locations": "London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida", "NCTID": "NCT04991480", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "1", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "2", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "3", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "4", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "5", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "6", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "7", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "8", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "9", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "10", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "11", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "12", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "13", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "14", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "15", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "16", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "17", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "18", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "19", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "20", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "21", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "22", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "23", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "24", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "25", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "26", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "27", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "28", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "29", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "30", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "31", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "32", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "33", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "34", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "35", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "36", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "37", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "38", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "39", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "40", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "41", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "42", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "43", "ReferenceId": "10096247", "FullCitation": "Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247", "Include": "true"}, {"number": "44", "ReferenceId": "9331072", "FullCitation": "Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072", "Include": "true"}, {"number": "45", "ReferenceId": "10188904", "FullCitation": "Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904", "Include": "true"}, {"number": "46", "ReferenceId": "11504770", "FullCitation": "Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770", "Include": "true"}, {"number": "47", "ReferenceId": "9796977", "FullCitation": "Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977", "Include": "true"}, {"number": "48", "ReferenceId": "10560660", "FullCitation": "Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660", "Include": "true"}, {"number": "49", "ReferenceId": "17974913", "FullCitation": "Furnari FB, et al. Genes Dev. (2007) pmid: 17974913", "Include": "true"}, {"number": "50", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "51", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "52", "ReferenceId": "10213484", "FullCitation": "Sano T, et al. Cancer Res. (1999) pmid: 10213484", "Include": "true"}, {"number": "53", "ReferenceId": "21134002", "FullCitation": "Srividya MR, et al. Neuropathology (2011) pmid: 21134002", "Include": "true"}, {"number": "54", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "55", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "56", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "57", "ReferenceId": "15998902", "FullCitation": "Galanis E, et al. J. Clin. Oncol. (2005) pmid: 15998902", "Include": "true"}, {"number": "58", "ReferenceId": "19018475", "FullCitation": "Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475", "Include": "true"}, {"number": "59", "ReferenceId": "22160854", "FullCitation": "Mason WP, et al. Invest New Drugs (2012) pmid: 22160854", "Include": "true"}, {"number": "60", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "61", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "62", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "63", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "64", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "65", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "66", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "67", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "68", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "69", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "70", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "71", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "72", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "73", "ReferenceId": "18483217", "FullCitation": "Andrae J, et al. Genes Dev. (2008) pmid: 18483217", "Include": "true"}, {"number": "74", "ReferenceId": "15175998", "FullCitation": "Semin. Oncol. (2004) pmid: 15175998", "Include": "true"}, {"number": "75", "ReferenceId": "15928335", "FullCitation": "Corless CL, et al. J. Clin. Oncol. (2005) pmid: 15928335", "Include": "true"}, {"number": "76", "ReferenceId": "24132921", "FullCitation": "Dai J, et al. Clin. Cancer Res. (2013) pmid: 24132921", "Include": "true"}, {"number": "77", "ReferenceId": "22745105", "FullCitation": "Heinrich MC, et al. Clin. Cancer Res. (2012) pmid: 22745105", "Include": "true"}, {"number": "78", "ReferenceId": "22718859", "FullCitation": "Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859", "Include": "true"}, {"number": "79", "ReferenceId": "15685537", "FullCitation": "Debiec_Rychter M, et al. Gastroenterology (2005) pmid: 15685537", "Include": "true"}, {"number": "80", "ReferenceId": "18955451", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955451", "Include": "true"}, {"number": "81", "ReferenceId": "14645423", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423", "Include": "true"}, {"number": "82", "ReferenceId": "18955458", "FullCitation": "Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458", "Include": "true"}, {"number": "83", "ReferenceId": "22665524", "FullCitation": "Heinrich MC, et al. Mol. Cancer Ther. (2012) pmid: 22665524", "Include": "true"}, {"number": "84", "ReferenceId": "20972453", "FullCitation": "von Bubnoff N, et al. Oncogene (2011) pmid: 20972453", "Include": "true"}, {"number": "85", "ReferenceId": "26130666", "FullCitation": "Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666", "Include": "true"}, {"number": "86", "ReferenceId": "27573554", "FullCitation": "Byrgazov K, et al. Leukemia (2017) pmid: 27573554", "Include": "true"}, {"number": "87", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "88", "ReferenceId": "18772890", "FullCitation": "Nature (2008) pmid: 18772890", "Include": "true"}, {"number": "89", "ReferenceId": "29625048", "FullCitation": "Hoadley KA, et al. Cell (2018) pmid: 29625048", "Include": "true"}, {"number": "90", "ReferenceId": "29596782", "FullCitation": "Ellrott K, et al. Cell Syst (2018) pmid: 29596782", "Include": "true"}, {"number": "91", "ReferenceId": "29622463", "FullCitation": "Taylor AM, et al. Cancer Cell (2018) pmid: 29622463", "Include": "true"}, {"number": "92", "ReferenceId": "29617662", "FullCitation": "Gao Q, et al. Cell Rep (2018) pmid: 29617662", "Include": "true"}, {"number": "93", "ReferenceId": "29625055", "FullCitation": "Liu J, et al. Cell (2018) pmid: 29625055", "Include": "true"}, {"number": "94", "ReferenceId": "29625050", "FullCitation": "Sanchez_Vega F, et al. Cell (2018) pmid: 29625050", "Include": "true"}, {"number": "95", "ReferenceId": "26824661", "FullCitation": "Ceccarelli M, et al. Cell (2016) pmid: 26824661", "Include": "true"}, {"number": "96", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "97", "ReferenceId": "28472509", "FullCitation": "Thomas AA, et al. Neuro_oncology (2017) pmid: 28472509", "Include": "true"}, {"number": "98", "ReferenceId": "23817572", "FullCitation": "Jones DT, et al. Nat. Genet. (2013) pmid: 23817572", "Include": "true"}, {"number": "99", "ReferenceId": "29888103", "FullCitation": "Song K, et al. Am J Cancer Res (2018) pmid: 29888103", "Include": "true"}, {"number": "100", "ReferenceId": "23074200", "FullCitation": "Alentorn A, et al. Neuro_oncology (2012) pmid: 23074200", "Include": "true"}, {"number": "101", "ReferenceId": "23412337", "FullCitation": "Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337", "Include": "true"}, {"number": "102", "ReferenceId": "23438035", "FullCitation": "Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035", "Include": "true"}, {"number": "103", "ReferenceId": "22806436", "FullCitation": "Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436", "Include": "true"}, {"number": "104", "ReferenceId": "17666373", "FullCitation": "Baccarani M, et al. Haematologica (2007) pmid: 17666373", "Include": "true"}, {"number": "105", "ReferenceId": "25658984", "FullCitation": "Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984", "Include": "true"}, {"number": "106", "ReferenceId": "12660384", "FullCitation": "Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384", "Include": "true"}, {"number": "107", "ReferenceId": "17555450", "FullCitation": "Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450", "Include": "true"}, {"number": "108", "ReferenceId": "15010069", "FullCitation": "Debiec_Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069", "Include": "true"}, {"number": "109", "ReferenceId": "20473908", "FullCitation": "Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908", "Include": "true"}, {"number": "110", "ReferenceId": "24638008", "FullCitation": "Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008", "Include": "true"}, {"number": "111", "ReferenceId": "16406018", "FullCitation": "Florian S, et al. Leuk. Res. (2006) pmid: 16406018", "Include": "true"}, {"number": "112", "ReferenceId": "27051816", "FullCitation": "Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816", "Include": "true"}, {"number": "113", "ReferenceId": "12808148", "FullCitation": "Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148", "Include": "true"}, {"number": "114", "ReferenceId": "19120352", "FullCitation": "Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352", "Include": "true"}, {"number": "115", "ReferenceId": "24009127", "FullCitation": "Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127", "Include": "true"}, {"number": "116", "ReferenceId": "21093052", "FullCitation": "Hus M, et al. Leuk. Res. (2011) pmid: 21093052", "Include": "true"}, {"number": "117", "ReferenceId": "20303172", "FullCitation": "Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172", "Include": "true"}, {"number": "118", "ReferenceId": "19735261", "FullCitation": "Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261", "Include": "true"}, {"number": "119", "ReferenceId": "19013640", "FullCitation": "Jain N, et al. Leuk. Res. (2009) pmid: 19013640", "Include": "true"}, {"number": "120", "ReferenceId": "17299092", "FullCitation": "Jovanovic JV, et al. Blood (2007) pmid: 17299092", "Include": "true"}, {"number": "121", "ReferenceId": "22150077", "FullCitation": "Kang HJ, et al. Acta Oncol (2012) pmid: 22150077", "Include": "true"}, {"number": "122", "ReferenceId": "14504092", "FullCitation": "Klion AD, et al. Blood (2004) pmid: 14504092", "Include": "true"}, {"number": "123", "ReferenceId": "19192229", "FullCitation": "Kobayashi M, et al. Respirology (2009) pmid: 19192229", "Include": "true"}, {"number": "124", "ReferenceId": "24635438", "FullCitation": "Koc\u00e1kov\u00e1 I, et al. Klin Onkol (2014) pmid: 24635438", "Include": "true"}, {"number": "125", "ReferenceId": "18950453", "FullCitation": "Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453", "Include": "true"}, {"number": "126", "ReferenceId": "22645636", "FullCitation": "Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636", "Include": "true"}, {"number": "127", "ReferenceId": "19910029", "FullCitation": "Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029", "Include": "true"}, {"number": "128", "ReferenceId": "16856885", "FullCitation": "Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885", "Include": "true"}, {"number": "129", "ReferenceId": "12842979", "FullCitation": "Pardanani A, et al. Blood (2003) pmid: 12842979", "Include": "true"}, {"number": "130", "ReferenceId": "15284118", "FullCitation": "Pardanani A, et al. Blood (2004) pmid: 15284118", "Include": "true"}, {"number": "131", "ReferenceId": "27120808", "FullCitation": "Qu SQ, et al. Oncotarget (2016) pmid: 27120808", "Include": "true"}, {"number": "132", "ReferenceId": "16498388", "FullCitation": "Score J, et al. Leukemia (2006) pmid: 16498388", "Include": "true"}, {"number": "133", "ReferenceId": "24669761", "FullCitation": "Shah S, et al. J Hematol Oncol (2014) pmid: 24669761", "Include": "true"}, {"number": "134", "ReferenceId": "26319757", "FullCitation": "Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757", "Include": "true"}, {"number": "135", "ReferenceId": "20609486", "FullCitation": "Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486", "Include": "true"}, {"number": "136", "ReferenceId": "15618966", "FullCitation": "von Bubnoff N, et al. Leukemia (2005) pmid: 15618966", "Include": "true"}, {"number": "137", "ReferenceId": "16845659", "FullCitation": "Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659", "Include": "true"}, {"number": "138", "ReferenceId": "23157309", "FullCitation": "Al_Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309", "Include": "true"}, {"number": "139", "ReferenceId": "16645167", "FullCitation": "Lierman E, et al. Blood (2006) pmid: 16645167", "Include": "true"}, {"number": "140", "ReferenceId": "19212337", "FullCitation": "Lierman E, et al. Leukemia (2009) pmid: 19212337", "Include": "true"}, {"number": "141", "ReferenceId": "21818111", "FullCitation": "Metzgeroth G, et al. Leukemia (2012) pmid: 21818111", "Include": "true"}, {"number": "142", "ReferenceId": "22294526", "FullCitation": "Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526", "Include": "true"}, {"number": "143", "ReferenceId": "24057647", "FullCitation": "Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647", "Include": "true"}, {"number": "144", "ReferenceId": "20832858", "FullCitation": "Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858", "Include": "true"}, {"number": "145", "ReferenceId": "18794084", "FullCitation": "Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084", "Include": "true"}, {"number": "146", "ReferenceId": "17087936", "FullCitation": "Weisberg E, et al. Gastroenterology (2006) pmid: 17087936", "Include": "true"}, {"number": "147", "ReferenceId": "26396737", "FullCitation": "Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737", "Include": "true"}, {"number": "148", "ReferenceId": "28031906", "FullCitation": "Grellety T, et al. Future Sci OA (2015) pmid: 28031906", "Include": "true"}, {"number": "149", "ReferenceId": "25905001", "FullCitation": "Koll\u00e0r A, et al. Clin Sarcoma Res (2014) pmid: 25905001", "Include": "true"}, {"number": "150", "ReferenceId": "29093181", "FullCitation": "Evans EK, et al. Sci Transl Med (2017) pmid: 29093181", "Include": "true"}, {"number": "151", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "152", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "153", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "154", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "155", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "156", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "157", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "158", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "159", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "160", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "161", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "162", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "163", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "164", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "165", "ReferenceId": "20195608", "FullCitation": "Bacher U, et al. Ann. Hematol. (2010) pmid: 20195608", "Include": "true"}, {"number": "166", "ReferenceId": "10347229", "FullCitation": "Miyake S, et al. J. Biol. Chem. (1999) pmid: 10347229", "Include": "true"}, {"number": "167", "ReferenceId": "23127761", "FullCitation": "Polzer H, et al. Exp. Hematol. (2013) pmid: 23127761", "Include": "true"}, {"number": "168", "ReferenceId": "9851973", "FullCitation": "Levkowitz G, et al. Genes Dev. (1998) pmid: 9851973", "Include": "true"}, {"number": "169", "ReferenceId": "23400592", "FullCitation": "Bunda S, et al. Cancer Res. (2013) pmid: 23400592", "Include": "true"}, {"number": "170", "ReferenceId": "7925293", "FullCitation": "Andoniou CE, et al. EMBO J. (1994) pmid: 7925293", "Include": "true"}, {"number": "171", "ReferenceId": "22315494", "FullCitation": "Aranaz P, et al. Haematologica (2012) pmid: 22315494", "Include": "true"}, {"number": "172", "ReferenceId": "20622007", "FullCitation": "Fernandes MS, et al. J. Biol. Chem. (2010) pmid: 20622007", "Include": "true"}, {"number": "173", "ReferenceId": "19387008", "FullCitation": "Grand FH, et al. Blood (2009) pmid: 19387008", "Include": "true"}, {"number": "174", "ReferenceId": "23696637", "FullCitation": "Javadi M, et al. J. Biol. Chem. (2013) pmid: 23696637", "Include": "true"}, {"number": "175", "ReferenceId": "15117950", "FullCitation": "Kassenbrock CK, et al. J. Biol. Chem. (2004) pmid: 15117950", "Include": "true"}, {"number": "176", "ReferenceId": "10635327", "FullCitation": "Levkowitz G, et al. Mol. Cell (1999) pmid: 10635327", "Include": "true"}, {"number": "177", "ReferenceId": "19571318", "FullCitation": "Loh ML, et al. Blood (2009) pmid: 19571318", "Include": "true"}, {"number": "178", "ReferenceId": "20619386", "FullCitation": "Martinelli S, et al. Am. J. Hum. Genet. (2010) pmid: 20619386", "Include": "true"}, {"number": "179", "ReferenceId": "22591685", "FullCitation": "Saito Y, et al. Leuk. Res. (2012) pmid: 22591685", "Include": "true"}, {"number": "180", "ReferenceId": "19620960", "FullCitation": "Sanada M, et al. Nature (2009) pmid: 19620960", "Include": "true"}, {"number": "181", "ReferenceId": "22053108", "FullCitation": "Score J, et al. Blood (2012) pmid: 22053108", "Include": "true"}, {"number": "182", "ReferenceId": "21494262", "FullCitation": "Shiba N, et al. Leukemia (2011) pmid: 21494262", "Include": "true"}, {"number": "183", "ReferenceId": "15581361", "FullCitation": "Standaert ML, et al. Biochemistry (2004) pmid: 15581361", "Include": "true"}, {"number": "184", "ReferenceId": "20126411", "FullCitation": "Tan YH, et al. PLoS ONE (2010) pmid: 20126411", "Include": "true"}, {"number": "185", "ReferenceId": "11239464", "FullCitation": "Thien CB, et al. Mol. Cell (2001) pmid: 11239464", "Include": "true"}, {"number": "186", "ReferenceId": "16246327", "FullCitation": "Visser GD, et al. Exp. Cell Res. (2005) pmid: 16246327", "Include": "true"}, {"number": "187", "ReferenceId": "26676746", "FullCitation": "Li M, et al. Cancer Res. (2016) pmid: 26676746", "Include": "true"}, {"number": "188", "ReferenceId": "27073553", "FullCitation": "Jing Z, et al. Oncol Lett (2016) pmid: 27073553", "Include": "true"}, {"number": "189", "ReferenceId": "25450678", "FullCitation": "Seong MW, et al. Biochem. Biophys. Res. Commun. (2014) pmid: 25450678", "Include": "true"}, {"number": "190", "ReferenceId": "24458840", "FullCitation": "Stevens BM, et al. Stem Cells (2014) pmid: 24458840", "Include": "true"}, {"number": "191", "ReferenceId": "11847211", "FullCitation": "Mancini A, et al. J. Biol. Chem. (2002) pmid: 11847211", "Include": "true"}, {"number": "192", "ReferenceId": "9653117", "FullCitation": "Miyake S, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9653117", "Include": "true"}, {"number": "193", "ReferenceId": "16780420", "FullCitation": "Masson K, et al. Biochem. J. (2006) pmid: 16780420", "Include": "true"}, {"number": "194", "ReferenceId": "17372230", "FullCitation": "Singh AJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17372230", "Include": "true"}, {"number": "195", "ReferenceId": "24553136", "FullCitation": "Paolino M, et al. Nature (2014) pmid: 24553136", "Include": "true"}, {"number": "196", "ReferenceId": "26675259", "FullCitation": "Patwardhan PP, et al. Oncotarget (2016) pmid: 26675259", "Include": "true"}, {"number": "197", "ReferenceId": "17486068", "FullCitation": "Shtiegman K, et al. Oncogene (2007) pmid: 17486068", "Include": "true"}, {"number": "198", "ReferenceId": "17699773", "FullCitation": "Padr\u00f3n D, et al. Cancer Res. (2007) pmid: 17699773", "Include": "true"}, {"number": "199", "ReferenceId": "17695511", "FullCitation": "Hosaka T, et al. Anticancer Res. () pmid: 17695511", "Include": "true"}, {"number": "200", "ReferenceId": "16969069", "FullCitation": "Han W, et al. Cancer Biol. Ther. (2006) pmid: 16969069", "Include": "true"}, {"number": "201", "ReferenceId": "16849543", "FullCitation": "Yang S, et al. Cancer Res. (2006) pmid: 16849543", "Include": "true"}, {"number": "202", "ReferenceId": "17446348", "FullCitation": "Sargin B, et al. Blood (2007) pmid: 17446348", "Include": "true"}, {"number": "203", "ReferenceId": "21768087", "FullCitation": "Oshikawa G, et al. J. Biol. Chem. (2011) pmid: 21768087", "Include": "true"}, {"number": "204", "ReferenceId": "19276253", "FullCitation": "Reindl C, et al. Clin. Cancer Res. (2009) pmid: 19276253", "Include": "true"}, {"number": "205", "ReferenceId": "22990016", "FullCitation": "Taylor SJ, et al. Blood (2012) pmid: 22990016", "Include": "true"}, {"number": "206", "ReferenceId": "22246246", "FullCitation": "Makishima H, et al. Leukemia (2012) pmid: 22246246", "Include": "true"}, {"number": "207", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "208", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "209", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "210", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "211", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "212", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "213", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "214", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "215", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "216", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "217", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "218", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "219", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "220", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "221", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "222", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "223", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "224", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "225", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "226", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "227", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "228", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "229", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "230", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "231", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "232", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "233", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "234", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "235", "ReferenceId": "31263031", "FullCitation": "Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031", "Include": "true"}, {"number": "236", "ReferenceId": "20129251", "FullCitation": "Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251", "Include": "true"}, {"number": "237", "ReferenceId": "16909113", "FullCitation": "Weber RG, et al. Oncogene (2007) pmid: 16909113", "Include": "true"}, {"number": "238", "ReferenceId": "11303791", "FullCitation": "Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791", "Include": "true"}, {"number": "239", "ReferenceId": "11489817", "FullCitation": "Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817", "Include": "true"}, {"number": "240", "ReferenceId": "21713760", "FullCitation": "Feng J, et al. Cancer (2012) pmid: 21713760", "Include": "true"}, {"number": "241", "ReferenceId": "21636552", "FullCitation": "Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552", "Include": "true"}, {"number": "242", "ReferenceId": "21843312", "FullCitation": "Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312", "Include": "true"}, {"number": "243", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "244", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "245", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "246", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "247", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "248", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "249", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "250", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "251", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "252", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "253", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "254", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "255", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "256", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "257", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "258", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "259", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "260", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "261", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "262", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "263", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "264", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "265", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "266", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "267", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "268", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "269", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "270", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "271", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "272", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "273", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "274", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "275", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "276", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "277", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "278", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "279", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "280", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "281", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "282", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "283", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "284", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "285", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "286", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "287", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "288", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "289", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "290", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "291", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "292", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "293", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "294", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "295", "ReferenceId": "23898124", "FullCitation": "Zustovich F, et al. Anticancer Res. (2013) pmid: 23898124", "Include": "true"}, {"number": "296", "ReferenceId": "20443129", "FullCitation": "Reardon DA, et al. J. Neurooncol. (2011) pmid: 20443129", "Include": "true"}, {"number": "297", "ReferenceId": "23099651", "FullCitation": "Lee EQ, et al. Neuro_oncology (2012) pmid: 23099651", "Include": "true"}, {"number": "298", "ReferenceId": "23328813", "FullCitation": "Peereboom DM, et al. Neuro_oncology (2013) pmid: 23328813", "Include": "true"}, {"number": "299", "ReferenceId": "24786603", "FullCitation": "Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603", "Include": "true"}, {"number": "300", "ReferenceId": "24803676", "FullCitation": "Karajannis MA, et al. Neuro_oncology (2014) pmid: 24803676", "Include": "true"}, {"number": "301", "ReferenceId": "25674429", "FullCitation": "Hassler MR, et al. Springerplus (2014) pmid: 25674429", "Include": "true"}, {"number": "302", "ReferenceId": "19789313", "FullCitation": "Razis E, et al. Clin. Cancer Res. (2009) pmid: 19789313", "Include": "true"}, {"number": "303", "ReferenceId": "19904263", "FullCitation": "Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263", "Include": "true"}, {"number": "304", "ReferenceId": "22371319", "FullCitation": "Reardon DA, et al. Cancer (2012) pmid: 22371319", "Include": "true"}, {"number": "305", "ReferenceId": "17377585", "FullCitation": "Metzgeroth G, et al. Leukemia (2007) pmid: 17377585", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_04_10 22:56:48", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "816x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain glioblastoma (GBM)", "flowcell_analysis": "2000028545", "gender": "male", "pathology_diagnosis": "Glioblastoma, GBM", "percent_tumor_nuclei": "60", "pipeline_version": "v3.21.0", "purity_assessment": "79.95", "specimen": "ORD_1602304_01*US1530025.01", "study": "Chugai Commercial F1CDx v2", "test_request": "ORD_1602304_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "829.74", "name": "SQ_US1530025.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.2008", "cds_effect": "407G>A", "depth": "498", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "20.08", "position": "chr10:89692923", "protein_effect": "C136Y", "status": "known", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1530025.01_1"}}, {"allele_fraction": "0.1463", "cds_effect": "4987A>G", "depth": "499", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "14.63", "position": "chr19:15281269", "protein_effect": "M1663V", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1530025.01_1"}}, {"allele_fraction": "0.472", "cds_effect": "3209C>T", "depth": "589", "equivocal": "false", "functional_effect": "missense", "gene": "TSC2", "percent_reads": "47.2", "position": "chr16:2129354", "protein_effect": "T1070M", "status": "unknown", "strand": "+", "transcript": "NM_000548", "dna_evidence": {"sample": "SQ_US1530025.01_1"}}, {"allele_fraction": "0.1696", "cds_effect": "2524G>T", "depth": "1586", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "16.96", "position": "chr4:55152092", "protein_effect": "D842Y", "status": "known", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1530025.01_1"}}, {"allele_fraction": "0.6581", "cds_effect": "238C>T", "depth": "503", "equivocal": "false", "functional_effect": "nonsense", "gene": "CDKN2A", "percent_reads": "65.81", "position": "chr9:21971120", "protein_effect": "R80*", "status": "known", "strand": "_", "transcript": "NM_000077", "dna_evidence": {"sample": "SQ_US1530025.01_1"}}, {"allele_fraction": "0.3238", "cds_effect": "1228_92_1231>G", "depth": "1016", "equivocal": "false", "functional_effect": "splice", "gene": "CBL", "percent_reads": "32.38", "position": "chr11:119149128", "protein_effect": "splice site 1228_92_1231>G", "status": "likely", "strand": "+", "transcript": "NM_005188", "dna_evidence": {"sample": "SQ_US1530025.01_1"}}, {"allele_fraction": "0.4646", "cds_effect": "490A>T", "depth": "353", "equivocal": "false", "functional_effect": "missense", "gene": "SDHC", "percent_reads": "46.46", "position": "chr1:161332203", "protein_effect": "M164L", "status": "unknown", "strand": "+", "transcript": "NM_003001", "dna_evidence": {"sample": "SQ_US1530025.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.21", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}